Schulich School of Medicine & Dentistry, Western University, London, ON, Canada.
Department of Otolaryngology-Head & Neck Surgery, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada.
Ann Otol Rhinol Laryngol. 2024 Jun;133(6):560-565. doi: 10.1177/00034894241235523. Epub 2024 Mar 3.
This retrospective review documents the experience of ipratropium bromide use among pediatric patients with sialorrhea at our multidisciplinary sialorrhea clinic at Children's Hospital at London Health Sciences Centre (LHSC).
A retrospective chart review of patients diagnosed with sialorrhea at our multidisciplinary clinic between January 2015 and June 2021 was completed. Data on patient demographics, comorbidities, clinical presentation, previous interventions, quality of life, and medication adverse side effects was collected. Drooling Frequency and Severity Scale (DFSS) scores were reviewed to compare sialorrhea management pre- and post-treatment with topical 0.03% ipratropium bromide nasal solution. A descriptive analysis and Wilcoxon signed rank tests were conducted to compare pre- versus post-treatment DFSS scores.
A total of 12 patients presented for follow-up and were included in the final analysis. At the pre-treatment visit, the median DFSS score was 4 for frequency and 5 for severity. Post-treatment, median DFSS score was 3 for frequency and 4.5 for severity, ( = .020 and .129, respectively). Minimal adverse effects were encountered.
Ipratropium bromide provided a statistically significant benefit for drooling frequency in the patients studied and may present an additional topical medical option for pediatric sialorrhea with limited adverse effects.
本回顾性研究记录了我院多学科涎液过多症诊所使用溴化异丙托品治疗儿科涎液过多症患者的经验。
对 2015 年 1 月至 2021 年 6 月期间在我院多学科诊所被诊断为涎液过多症的患者进行了回顾性图表审查。收集了患者人口统计学、合并症、临床表现、既往干预措施、生活质量和药物不良反应等数据。回顾了流涎频率和严重程度量表（DFSS）评分，以比较使用 0.03%溴化异丙托品鼻用溶液局部治疗前后的涎液过多症管理情况。采用描述性分析和 Wilcoxon 符号秩检验比较治疗前后的 DFSS 评分。
共有 12 名患者接受随访并纳入最终分析。在治疗前就诊时，DFSS 评分的中位数为 4 分（频率）和 5 分（严重程度）。治疗后，DFSS 评分的中位数为 3 分（频率）和 4.5 分（严重程度），（ = .020 和.129，分别）。仅出现轻微不良反应。
在研究的患者中，溴化异丙托品治疗流涎频率具有统计学意义的益处，并且可能为儿童涎液过多症提供一种额外的局部治疗选择，不良反应有限。
